

Andrea L Cox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6860388/publications.pdf>

Version: 2024-02-01

126
papers

9,925
citations

57758

44
h-index

37204

96
g-index

145
all docs

145
docs citations

145
times ranked

9893
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Differential Cytokine Signatures of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza Infection Highlight Key Differences in Pathobiology. <i>Clinical Infectious Diseases</i> , 2022, 74, 254-262. | 5.8 | 28 |
| 2 | The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2022, 74, 1268-1270. | 5.8 | 118 |
| 3 | A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 1253-1260. | 4.7 | 73 |
| 4 | B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection. <i>PLoS Pathogens</i> , 2022, 18, e1010179. | 4.7 | 6 |
| 5 | Higher Proinflammatory Cytokines Are Associated With Increased Antibody Titer After a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2022, 106, 835-841. | 1.0 | 15 |
| 6 | Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQ1 ²¹ . <i>American Journal of Human Genetics</i> , 2022, 109, 299-310. | 6.2 | 6 |
| 7 | Differentiation of Individuals Previously Infected with and Vaccinated for SARS-CoV-2 in an Inner-City Emergency Department. <i>Journal of Clinical Microbiology</i> , 2022, 60, jcm0239021. | 3.9 | 5 |
| 8 | Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. <i>JCI Insight</i> , 2022, 7, . | 5.0 | 12 |
| 9 | IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. <i>JCI Insight</i> , 2022, 7, . | 5.0 | 23 |
| 10 | Continued Virus-Specific Antibody-Secreting Cell Production, Avidity Maturation and B Cell Evolution in Patients Hospitalized with COVID-19. <i>Viral Immunology</i> , 2022, 35, 259-272. | 1.3 | 4 |
| 11 | A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response. <i>Transplantation</i> , 2022, 106, 1440-1444. | 1.0 | 49 |
| 12 | SARS-CoV-2-specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge. <i>JCI Insight</i> , 2022, 7, . | 5.0 | 15 |
| 13 | Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2022, 9, . | 0.9 | 5 |
| 14 | SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection. <i>EBioMedicine</i> , 2022, 80, 104048. | 6.1 | 12 |
| 15 | Cross-reactive antibodies facilitate innate sensing of dengue and Zika viruses. <i>JCI Insight</i> , 2022, 7, . | 5.0 | 2 |
| 16 | Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency. <i>Journal of Clinical Investigation</i> , 2022, 132, . | 8.2 | 5 |
| 17 | Markers of endothelial cell activation are associated with the severity of pulmonary disease in COVID-19. <i>PLoS ONE</i> , 2022, 17, e0268296. | 2.5 | 12 |
| 18 | A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 2090-2098. | 4.0 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2021, 384, 541-549. | 27.0 | 101 |
| 20 | Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. <i>Cell Reports</i> , 2021, 34, 108863. | 6.4 | 92 |
| 21 | People with HIV-1 Demonstrate Type 1 Interferon Refractoriness Associated with Upregulated USP18. <i>Journal of Virology</i> , 2021, 95, . | 3.4 | 4 |
| 22 | Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. <i>Journal of Clinical Investigation</i> , 2021, 131, . | 8.2 | 72 |
| 23 | Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. <i>JCI Insight</i> , 2021, 6, . | 5.0 | 86 |
| 24 | Delayed Rise of Oral Fluid Antibodies, Elevated BMI, and Absence of Early Fever Correlate With Longer Time to SARS-CoV-2 RNA Clearance in a Longitudinally Sampled Cohort of COVID-19 Outpatients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab195. | 0.9 | 13 |
| 25 | Durable SARS-CoV-2 B cell immunity after mild or severe disease. <i>Journal of Clinical Investigation</i> , 2021, 131, . | 8.2 | 76 |
| 26 | Distinct Cytokine and Chemokine Dysregulation in Hospitalized Children With Acute Coronavirus Disease 2019 and Multisystem Inflammatory Syndrome With Similar Levels of Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 Shedding. <i>Journal of Infectious Diseases</i> , 2021, 224, 606-615. | 4.0 | 30 |
| 27 | Interleukin-18 and tumor necrosis factor- α are elevated in solid organ transplant recipients with possible cytomegalovirus end-organ disease. <i>Transplant Infectious Disease</i> , 2021, 23, e13682. | 1.7 | 4 |
| 28 | The NIH Lipo-COVID Study: A Pilot NMR Investigation of Lipoprotein Subfractions and Other Metabolites in Patients with Severe COVID-19. <i>Biomedicines</i> , 2021, 9, 1090. | 3.2 | 22 |
| 29 | Controlled Human Infection Model "Fast Track to HCV Vaccine?". <i>New England Journal of Medicine</i> , 2021, 385, 1235-1240. | 27.0 | 22 |
| 30 | High-value laboratory testing for hospitalized COVID-19 patients: a review. <i>Future Virology</i> , 2021, 16, 691-705. | 1.8 | 11 |
| 31 | The Clinical Course of COVID-19 in the Outpatient Setting: A Prospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab007. | 0.9 | 55 |
| 32 | Plasma virome and the risk of blood-borne infection in persons with substance use disorder. <i>Nature Communications</i> , 2021, 12, 6909. | 12.8 | 8 |
| 33 | Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection. <i>Clinical Infectious Diseases</i> , 2020, 70, 123-131. | 5.8 | 7 |
| 34 | Challenges and Promise of a Hepatitis C Virus Vaccine. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036947. | 6.2 | 30 |
| 35 | Progress towards elimination goals for viral hepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 533-542. | 17.8 | 118 |
| 36 | Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. <i>Genes and Immunity</i> , 2020, 21, 348-359. | 4.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Antibody avidity-based approach to estimate population-level incidence of hepatitis C. <i>Journal of Hepatology</i> , 2020, 73, 294-302. | 3.7 | 3 |
| 38 | Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIV-infected men in a community-based primary care setting. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1202-1213. | 2.0 | 1 |
| 39 | Herpes simplex virus type 1 inflammasome activation in proinflammatory human macrophages is dependent on NLRP3, ASC, and caspase-1. <i>PLoS ONE</i> , 2020, 15, e0229570. | 2.5 | 27 |
| 40 | Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine. <i>Clinical Infectious Diseases</i> , 2020, 71, 2986-2990. | 5.8 | 7 |
| 41 | Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2. <i>Journal of Virology</i> , 2019, 93, . | 3.4 | 37 |
| 42 | Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Gastroenterology</i> , 2019, 156, 1496-1507.e7. | 1.3 | 32 |
| 43 | Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. <i>Infection, Genetics and Evolution</i> , 2019, 71, 36-41. | 2.3 | 14 |
| 44 | Inconsistent temporal patterns of genetic variation of HCV among high-risk subjects may impact inference of transmission networks. <i>Infection, Genetics and Evolution</i> , 2019, 71, 1-6. | 2.3 | 2 |
| 45 | Trends in hepatitis C treatment initiation among HIV/hepatitis C virus-coinfected men engaged in primary care in a multisite community health centre in Maryland: a retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e027411. | 1.9 | 6 |
| 46 | Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. <i>Gastroenterology</i> , 2019, 156, 418-430. | 1.3 | 162 |
| 47 | Genomic variability of within-host hepatitis C variants in acute infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 476-484. | 2.0 | 6 |
| 48 | Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. <i>Journal of Clinical Investigation</i> , 2019, 129, 4786-4796. | 8.2 | 33 |
| 49 | The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. <i>Clinical Infectious Diseases</i> , 2018, 66, 20-28. | 5.8 | 21 |
| 50 | Complex patterns of Hepatitis-C virus longitudinal clustering in a high-risk population. <i>Infection, Genetics and Evolution</i> , 2018, 58, 77-82. | 2.3 | 12 |
| 51 | Opioids, Hepatitis C Virus Infection, and the Missing Vaccine. <i>American Journal of Public Health</i> , 2018, 108, 156-157. | 2.7 | 8 |
| 52 | Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?. <i>Trends in Microbiology</i> , 2018, 26, 854-864. | 7.7 | 39 |
| 53 | Interventional Radiation Oncology (IRO): Transition of a magnetic resonance simulator to a brachytherapy suite. <i>Brachytherapy</i> , 2018, 17, 587-596. | 0.5 | 7 |
| 54 | Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. <i>Cell Host and Microbe</i> , 2018, 24, 717-730.e5. | 11.0 | 78 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Medical school research ranking is associated with gender inequality in MSTP application rates. <i>BMC Medical Education</i> , 2018, 18, 187. | 2.4 | 15 |
| 56 | Balancing Research, Teaching, Clinical Care, and Family: Can Physician-Scientists Have it All?. <i>Journal of Infectious Diseases</i> , 2018, 218, S32-S35. | 4.0 | 8 |
| 57 | Systemic Elevation of Proinflammatory Interleukin 18 in HIV/HCV Coinfection versus HIV or HCV Mono-infection. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw771. | 5.8 | 17 |
| 58 | Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. <i>Infection, Genetics and Evolution</i> , 2017, 49, 88-96. | 2.3 | 8 |
| 59 | Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller. <i>EBioMedicine</i> , 2017, 16, 141-149. | 6.1 | 27 |
| 60 | Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. <i>Clinical Infectious Diseases</i> , 2017, 64, 860-869. | 5.8 | 61 |
| 61 | Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections. <i>Genes and Immunity</i> , 2017, 18, 82-87. | 4.1 | 6 |
| 62 | Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. <i>Scientific Reports</i> , 2017, 7, 15843. | 3.3 | 6 |
| 63 | Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 43-52. | 2.0 | 14 |
| 64 | Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. <i>Journal of Viral Hepatitis</i> , 2017, 24, 37-42. | 2.0 | 11 |
| 65 | Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. <i>JCI Insight</i> , 2017, 2, . | 5.0 | 129 |
| 66 | HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells. <i>Journal of Clinical Investigation</i> , 2017, 127, 4352-4364. | 8.2 | 17 |
| 67 | Continued Elevation of Interleukin-18 and Interferon- γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw118. | 0.9 | 19 |
| 68 | TGF β 1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. <i>Cancer Discovery</i> , 2016, 6, 1366-1381. | 9.4 | 196 |
| 69 | Favorable Socioeconomic Status and Recreational Polydrug Use Are Linked With Sexual Hepatitis C Virus Transmission Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw137. | 0.9 | 14 |
| 70 | Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. <i>Journal of Infectious Diseases</i> , 2016, 214, 1383-1389. | 4.0 | 16 |
| 71 | The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. <i>Drug and Alcohol Dependence</i> , 2016, 169, 156-162. | 3.2 | 10 |
| 72 | Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 344-352. | 4.0 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. <i>Gut</i> , 2016, 65, 112-123. | 12.1 | 30 |
| 74 | Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw024. | 0.9 | 1 |
| 75 | Prophylactic Vaccines for the Hepatitis C Virus. , 2016, , 325-346. | | 1 |
| 76 | Lessons from Nature: Understanding Immunity to HCV to Guide Vaccine Design. <i>PLoS Pathogens</i> , 2016, 12, e1005632. | 4.7 | 13 |
| 77 | IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes. <i>Antiviral Therapy</i> , 2015, 20, 805-814. | 1.0 | 4 |
| 78 | Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study. <i>PLoS ONE</i> , 2015, 10, e0122232. | 2.5 | 41 |
| 79 | Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection—the InC ³ Study. <i>Journal of Infectious Diseases</i> , 2015, 212, 1407-1419. | 4.0 | 82 |
| 80 | Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC ³ study. <i>Journal of Viral Hepatitis</i> , 2015, 22, 708-717. | 2.0 | 13 |
| 81 | Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release. <i>Journal of Virology</i> , 2015, 89, 9454-9464. | 3.4 | 19 |
| 82 | Global control of hepatitis C virus. <i>Science</i> , 2015, 349, 790-791. | 12.6 | 90 |
| 83 | HIV and HCV Activate the Inflammasome in Monocytes and Macrophages via Endosomal Toll-Like Receptors without Induction of Type 1 Interferon. <i>PLoS Pathogens</i> , 2014, 10, e1004082. | 4.7 | 159 |
| 84 | Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. <i>Hepatology</i> , 2014, 59, 2140-2151. | 7.3 | 230 |
| 85 | The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. <i>Hepatology</i> , 2014, 59, 109-120. | 7.3 | 320 |
| 86 | Not-so-innocent bystanders. <i>Nature</i> , 2014, 505, 492-493. | 27.8 | 19 |
| 87 | Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study. <i>Journal of Clinical Virology</i> , 2014, 61, 430-434. | 3.1 | 8 |
| 88 | Admixture analysis of spontaneous hepatitis C virus clearance in individuals of African descent. <i>Genes and Immunity</i> , 2014, 15, 241-246. | 4.1 | 9 |
| 89 | Monocytes Activate Natural Killer Cells via Inflammasome-Induced Interleukin 18 in Response to Hepatitis C Virus Replication. <i>Gastroenterology</i> , 2014, 147, 209-220.e3. | 1.3 | 81 |
| 90 | Making Sense of HIV Innate Sensing. <i>Immunity</i> , 2013, 39, 998-1000. | 14.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Hepatitis C Virus Vaccines Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2013, 57, S46-S50. | 5.8 | 31 |
| 92 | Immunity and Hepatitis C: A Review. <i>Current HIV/AIDS Reports</i> , 2013, 10, 51-58. | 3.1 | 25 |
| 93 | Frequent Longitudinal Sampling of Hepatitis C Virus Infection in Injection Drug Users Reveals Intermittently Detectable Viremia and Reinfection. <i>Clinical Infectious Diseases</i> , 2013, 56, 405-413. | 5.8 | 29 |
| 94 | Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. <i>International Journal of Epidemiology</i> , 2013, 42, 1649-1659. | 1.9 | 48 |
| 95 | Anti-inflammatory cytokines, pro-fibrogenic chemokines and persistence of acute HCV infection. <i>Journal of Viral Hepatitis</i> , 2013, 20, 404-413. | 2.0 | 20 |
| 96 | Evolution of CD8 ⁺ T Cell Responses after Acute PARV4 Infection. <i>Journal of Virology</i> , 2013, 87, 3087-3096. | 3.4 | 16 |
| 97 | Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts. <i>Annals of Internal Medicine</i> , 2013, 158, 235. | 3.9 | 187 |
| 98 | The More You Look, the More You Find: Effects of Hepatitis C Virus Testing Interval on Reinfection Incidence and Clearance and Implications for Future Vaccine Study Design. <i>Journal of Infectious Diseases</i> , 2012, 205, 1342-1350. | 4.0 | 64 |
| 99 | Immunogenicity and Cross-Reactivity of a Representative Ancestral Sequence in Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2012, 188, 5177-5188. | 0.8 | 28 |
| 100 | A Live-Attenuated <i>Listeria</i> Vaccine (ANZ-100) and a Live-Attenuated <i>Listeria</i> Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction. <i>Clinical Cancer Research</i> , 2012, 18, 858-868. | 7.0 | 304 |
| 101 | Computational Reconstruction of Bole1a, a Representative Synthetic Hepatitis C Virus Subtype 1a Genome. <i>Journal of Virology</i> , 2012, 86, 5915-5921. | 3.4 | 21 |
| 102 | Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 408-414. | 9.1 | 186 |
| 103 | Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. <i>Hepatology</i> , 2012, 55, 1684-1691. | 7.3 | 63 |
| 104 | Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors. <i>Aids</i> , 2011, 25, 385-387. | 2.2 | 20 |
| 105 | High Plasma Interleukin-18 Levels Mark the Acute Phase of Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2011, 204, 1730-1740. | 4.0 | 51 |
| 106 | Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. <i>Immunologic Research</i> , 2010, 47, 216-227. | 2.9 | 63 |
| 107 | Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. <i>Hepatology</i> , 2010, 52, 1581-1589. | 7.3 | 100 |
| 108 | Acceleration of Hepatitis C Virus Envelope Evolution in Humans Is Consistent with Progressive Humoral Immune Selection during the Transition from Acute to Chronic Infection. <i>Journal of Virology</i> , 2010, 84, 5067-5077. | 3.4 | 70 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Spontaneous Control of Primary Hepatitis C Virus Infection and Immunity Against Persistent Reinfection. <i>Gastroenterology</i> , 2010, 138, 315-324. | 1.3 | 316 |
| 110 | Rare Birds in North America: Acute Hepatitis C Cohorts. <i>Gastroenterology</i> , 2009, 136, 26-31. | 1.3 | 53 |
| 111 | Selection Pressure From Neutralizing Antibodies Drives Sequence Evolution During Acute Infection With Hepatitis C Virus. <i>Gastroenterology</i> , 2009, 136, 2377-2386. | 1.3 | 207 |
| 112 | Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2008, 15, 219-228. | 2.0 | 31 |
| 113 | Human Immunodeficiency Virus-Related Microbial Translocation and Progression of Hepatitis C. <i>Gastroenterology</i> , 2008, 135, 226-233. | 1.3 | 251 |
| 114 | Hepatitis C Virus Immune Escape via Exploitation of a Hole in the T Cell Repertoire. <i>Journal of Immunology</i> , 2008, 181, 6435-6446. | 0.8 | 61 |
| 115 | High-Programmed Death-1 Levels on Hepatitis C Virus-Specific T Cells during Acute Infection Are Associated with Viral Persistence and Require Preservation of Cognate Antigen during Chronic Infection. <i>Journal of Immunology</i> , 2008, 181, 8215-8225. | 0.8 | 114 |
| 116 | CD4+T Cell-Dependent Reduction in Hepatitis C Virus-Specific Humoral Immune Responses after HIV Infection. <i>Journal of Infectious Diseases</i> , 2007, 195, 857-863. | 4.0 | 33 |
| 117 | Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. <i>Hepatology</i> , 2005, 42, 104-112. | 7.3 | 211 |
| 118 | Humoral Immune Response in Acute Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2005, 41, 667-675. | 5.8 | 172 |
| 119 | Cellular immune selection with hepatitis C virus persistence in humans. <i>Journal of Experimental Medicine</i> , 2005, 201, 1741-1752. | 8.5 | 278 |
| 120 | Prospective Evaluation of Community-Acquired Acute-Phase Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2005, 40, 951-958. | 5.8 | 195 |
| 121 | Protection against persistence of hepatitis C. <i>Lancet</i> , The, 2002, 359, 1478-1483. | 13.7 | 426 |
| 122 | Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. <i>Science</i> , 1994, 264, 716-719. | 12.6 | 812 |
| 123 | Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 10275-10279. | 7.1 | 122 |
| 124 | Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. <i>Science</i> , 1992, 256, 1817-1820. | 12.6 | 672 |
| 125 | Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. <i>Science</i> , 1992, 255, 1261-1263. | 12.6 | 1,189 |
| 126 | Sequence analysis of peptides presented to the immune system by class I and class II MHC molecules. <i>The Protein Journal</i> , 1992, 11, 377-378. | 1.1 | 0 |